This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Novolin R (Regular Human Insulin)
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-PERMANENT HIGH
Off-label bodybuilding use carries acute lethal hypoglycemia risk for any non-diabetic. a user in this archetype is 20, lean, insulin-sensitive, untested AAS-naive — there is no scenario where exogenous insulin makes sense. Would change only if a user in this archetype develops type 1 diabetes (medically necessary) — which is unrelated to biohacker use.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload (this-archetype) | SKIP-PERMANENT | Lethal-overdose risk dwarfs any speculative benefit. Brain priority + hypoglycemia risk = automatic skip (severe hypoglycemia causes neuronal death). |
30-50, executive maintenance | SKIP-PERMANENT | for non-diabetic. If diabetic, follow endocrinologist. |
50+, mild cognitive decline | SKIP-PERMANENT | Hypoglycemia accelerates cognitive decline. |
Anxiety-prone | SKIP-PERMANENT | Hypoglycemia symptoms mimic panic — unbearable. |
High athletic load, tested status | SKIP-PERMANENT | WADA-prohibited (S2.4) — yes, even for non-diabetics. |
Sleep-disordered | SKIP-PERMANENT | Nocturnal hypoglycemia is a known killer. |
Recovery-focused | SKIP-PERMANENT | — |
Strength/anabolic-focused (35+, experienced AAS user, full medical supervision, accepts mortality risk) | T | is the only profile with any tradition of use, and even within IFBB-pro circles the deaths are well-known. Verdict still SKIP for any biohacker not already deeply embedded in supervised pro-bodybuilding context. Outside of that — SKIP-PERMANENT. |
Diabetic (T1DM, T2DM with insulin requirement) | PRIMARY TREATMENT | entirely different decision frame, follow endocrinology. |
- ★20-30, brain-priority, high cognitive workload (this-archetype)SKIP-PERMANENT
Lethal-overdose risk dwarfs any speculative benefit. Brain priority + hypoglycemia risk = automatic skip (severe hypoglycemia causes neuronal death).
- 30-50, executive maintenanceSKIP-PERMANENT
for non-diabetic. If diabetic, follow endocrinologist.
- 50+, mild cognitive declineSKIP-PERMANENT
Hypoglycemia accelerates cognitive decline.
- Anxiety-proneSKIP-PERMANENT
Hypoglycemia symptoms mimic panic — unbearable.
- High athletic load, tested statusSKIP-PERMANENT
WADA-prohibited (S2.4) — yes, even for non-diabetics.
- Sleep-disorderedSKIP-PERMANENT
Nocturnal hypoglycemia is a known killer.
- Recovery-focusedSKIP-PERMANENT
- Strength/anabolic-focused (35+, experienced AAS user, full medical supervision, accepts mortality risk)T
is the only profile with any tradition of use, and even within IFBB-pro circles the deaths are well-known. Verdict still SKIP for any biohacker not already deeply embedded in supervised pro-bodybuilding context. Outside of that — SKIP-PERMANENT.
- Diabetic (T1DM, T2DM with insulin requirement)PRIMARY TREATMENT
entirely different decision frame, follow endocrinology.
▸ Subjective experience (deep)
Within 30-60 min of injection without adequate carb intake: hunger, sweating, tremor, palpitations, anxiety, confusion → progressing to seizure, coma, death. With adequate carbs: warm flush, mild fatigue, hunger, "muscle pump" feeling some users report. No euphoric or cognitive effect.
▸ Tolerance + cycling deep dive
- Insulin sensitivity declines with chronic use of exogenous insulin in non-diabetics; can blunt endogenous response.
- No protective cycling — each dose carries the same hypoglycemia risk.
▸ Stacking deep dive
Synergistic with
- In bodybuilding context (DO NOT REPLICATE): Often stacked with HGH, IGF-1, AAS for "GH-insulin-AAS triad." Compounds risk dramatically.
Avoid stacking with
- Beta blockers (mask hypoglycemia symptoms — life-threatening combo)
- Alcohol (impairs gluconeogenesis, prolongs hypoglycemia)
- Other glucose-lowering agents
Neutral / safe co-administration
N/A — entire compound is unsafe in non-diabetic biohacker context.
▸ Drug interactions deep dive
- Glucocorticoids antagonize (raise glucose)
- Beta blockers mask warning signs of hypoglycemia (CRITICAL)
- Salicylates, ACE inhibitors potentiate hypoglycemia
- Sulfonylureas, GLP-1 agonists additive
▸ Pharmacogenomics
- INSR mutations (severe insulin resistance syndromes) — not relevant in biohacker population
- TCF7L2 variants modify diabetes risk but don't change exogenous insulin pharmacology
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| OTC (US) | Walmart ReliOn / pharmacy | ~$25/vial 100 IU/mL × 10 mL | high | Available without prescription in US — legality ≠ wisdom |
| Pharmacy Rx | various | similar | high | Often required outside US |
For the canonical archetype: Don't source. The cheap, easy access is part of why this kills people — no friction to acquisition.
▸ Biomarkers to track (deep)
- Baseline (if ever considering — DON'T): HbA1c, fasting glucose, fasting insulin, c-peptide, HOMA-IR
- During use (medical only): Capillary glucose 4-7×/day, HbA1c quarterly
- Post-cycle: N/A — not a cycling compound
▸ Controversies / open debates Live debate
- Does exogenous insulin add anything to a healthy lifter's hypertrophy beyond eating carbs? Mechanistically suspect — endogenous insulin already pulses high after a high-carb meal. Most peer-reviewed work suggests no meaningful added effect on protein synthesis above what amino acid intake already triggers via mTOR.
- OTC availability vs lethality. US allows OTC purchase of regular human insulin. This was a public-health win for diabetics who couldn't afford analogs but creates a low-friction path for misuse. Several bodybuilder coroner reports specifically cite the OTC accessibility.
- Intranasal insulin is a different file (intranasal-insulin.md) — that's a memory/cognition application without systemic glycemic effect because BBB delivery bypasses peripheral receptors. Don't conflate.
▸ Verdict change log
- 2026-05-06 — Initial verdict: SKIP-PERMANENT HIGH. Documented to close the loop on AAS-stacking insulin question and ensure no future "should the canonical archetype try slin?" recommendation accidentally surfaces. The answer is no, forever, for this profile.
▸ Open questions / gaps Open
- Whether any future fast-acting insulin formulation engineered for hypoglycemia-resistance (glucose-responsive) might change the calculus — currently theoretical.
- Long-term cancer signal of supraphysiologic insulin exposure in non-diabetic users — epidemiologic data essentially nonexistent due to off-label use being underground.
References
Konstantakos EK, Lord PF (2007) — Insulin abuse in athletes. Metab Syndr Relat Disord
PMID 18370811
View StudyHolt RIG, Sönksen PH (2008) — Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol
PMID 18454170, GH-IGF-insulin triad context
View StudyEvans PJ, Lynch RM (2003) — Insulin as a drug of abuse in body building. Br J Sports Med
foundational case-series review
View SourceDawson RT, Harrison MW (1997) — Use of insulin as an anabolic agent. Br J Sports Med
early UK warning
View SourceHeitkamp HC, et al. (2020) — Insulin abuse in bodybuilding: A systematic review. Substance Use & Misuse review series
modern systematic look
View SourceHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.